Fixing the Subscription Trap
The FTC’s Negative Option Rule do-over – and what’s at stake.
Heermann et al. v. Alchemee, LLC et al.
24-cv-7550, W.D. Mo.
(March 2024)
Howard et al. v. Alchemee, LLC and Taro Pharmaceutical USA, Inc.
24-cv-1834, C.D. Cal.
(March 2024)
Judt et al. v. Alchemee, LLC and Taro Pharmaceuticals U.S.A., Inc.
24-cv-2718, S.D.N.Y.
(April 2024)
O’Dea et al. v. Alchemee, LLC and Taro Pharmaceuticals U.S.A., Inc.
24-cv-2755, N.D. Ill.
(April 2024)
Ramos et al. v. Alchemee, LLC
24-cv-2230, N.D. Cal.
(March 2024)
Teron et al. v. Alchemee, LLC and Taro Pharmaceuticals U.S.A., Inc.
24-cv-7538, N.D. Cal.
(March 2024)
Proactiv
Misleadingly representing that products were safe when they contained, or were at risk of containing, the carcinogen benzene
Heermann case: Pending
Howard cases: Dismissed
Judt case: Voluntarily dismissed When a complaint is dismissed without prejudice, an amended version of the complaint can be refiled.
O’Dea case: Pending
Ramos case: Pending
Teron case: Pending
The FTC’s Negative Option Rule do-over – and what’s at stake.
Be wary of questionable and deceptive claims in origin stories.
Mounting lawsuits accuse Meta of breaking privacy promises.
Breaking down the fine print of this March Madness commercial.
Advertised $19.99 price deserves an official review.